Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals doubles Tryngolza sales forecast to $2 billion, positioning itself for robust 2026 growth amid a strong antisense oligonucleotide launch and strategic partnerships.

Ionis Pharmaceuticals Inc has made significant breakthroughs in biotechnology, including a 31% surge in stock value and positive Phase-III data for its drug Olezarsen, highlighting the company’s potential to revolutionize the treatment of severe blo…

Ionis Pharmaceuticals Inc. continues to demonstrate steady growth and promise, driven by positive developments in its RNA-targeted drug discovery and development, as well as analyst confidence and strategic endorsements.

Ionis Pharmaceuticals Inc. faces a mixed bag of financial news, with declining stock value and trading suspension, but also reaffirmed analyst confidence and a growing HDAC inhibitors market.

Ionis Pharmaceuticals Inc remains a leader in biotechnology, driven by innovative research and strategic partnerships, despite facing financial challenges.